167 related articles for article (PubMed ID: 16393431)
1. Development of an algorithm for using PINP to monitor treatment of patients with teriparatide.
Eastell R; Krege JH; Chen P; Glass EV; Reginster JY
Curr Med Res Opin; 2006 Jan; 22(1):61-6. PubMed ID: 16393431
[TBL] [Abstract][Full Text] [Related]
2. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
[TBL] [Abstract][Full Text] [Related]
3. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis.
Chen P; Satterwhite JH; Licata AA; Lewiecki EM; Sipos AA; Misurski DM; Wagman RB
J Bone Miner Res; 2005 Jun; 20(6):962-70. PubMed ID: 15883636
[TBL] [Abstract][Full Text] [Related]
4. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.
Delmas PD; Licata AA; Reginster JY; Crans GG; Chen P; Misurski DA; Wagman RB; Mitlak BH
Bone; 2006 Aug; 39(2):237-43. PubMed ID: 16563890
[TBL] [Abstract][Full Text] [Related]
5. PINP as an aid for monitoring patients treated with teriparatide.
Tsujimoto M; Chen P; Miyauchi A; Sowa H; Krege JH
Bone; 2011 Apr; 48(4):798-803. PubMed ID: 21168536
[TBL] [Abstract][Full Text] [Related]
6. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.
Burshell AL; Möricke R; Correa-Rotter R; Chen P; Warner MR; Dalsky GP; Taylor KA; Krege JH
Bone; 2010 Apr; 46(4):935-9. PubMed ID: 20060081
[TBL] [Abstract][Full Text] [Related]
7. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
Deal C; Omizo M; Schwartz EN; Eriksen EF; Cantor P; Wang J; Glass EV; Myers SL; Krege JH
J Bone Miner Res; 2005 Nov; 20(11):1905-11. PubMed ID: 16234962
[TBL] [Abstract][Full Text] [Related]
8. Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.
Eastell R; Chen P; Saag KG; Burshell AL; Wong M; Warner MR; Krege JH
Bone; 2010 Apr; 46(4):929-34. PubMed ID: 20060078
[TBL] [Abstract][Full Text] [Related]
9. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis.
Chen P; Miller PD; Delmas PD; Misurski DA; Krege JH
J Bone Miner Res; 2006 Nov; 21(11):1785-90. PubMed ID: 17002571
[TBL] [Abstract][Full Text] [Related]
10. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study.
Adachi JD; Hanley DA; Lorraine JK; Yu M
Clin Ther; 2007 Sep; 29(9):2055-67. PubMed ID: 18035204
[TBL] [Abstract][Full Text] [Related]
11. An algorithm using the early changes in PINP to predict the future BMD response for patients treated with daily teriparatide.
Niimi R; Kono T; Nishihara A; Hasegawa M; Matsumine A; Nakamura T; Kono T; Sudo A
Osteoporos Int; 2014 Jan; 25(1):377-84. PubMed ID: 23812597
[TBL] [Abstract][Full Text] [Related]
12. The effect of prior bisphosphonate exposure on the treatment response to teriparatide in clinical practice.
Middleton ET; Steel SA; Doherty SM
Calcif Tissue Int; 2007 Nov; 81(5):335-40. PubMed ID: 17938845
[TBL] [Abstract][Full Text] [Related]
13. Rapid and robust response of biochemical markers of bone formation to teriparatide therapy.
Glover SJ; Eastell R; McCloskey EV; Rogers A; Garnero P; Lowery J; Belleli R; Wright TM; John MR
Bone; 2009 Dec; 45(6):1053-8. PubMed ID: 19679211
[TBL] [Abstract][Full Text] [Related]
14. PINP as a biological response marker during teriparatide treatment for osteoporosis.
Krege JH; Lane NE; Harris JM; Miller PD
Osteoporos Int; 2014 Sep; 25(9):2159-71. PubMed ID: 24599274
[TBL] [Abstract][Full Text] [Related]
15. Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis.
Delmas PD; Munoz F; Black DM; Cosman F; Boonen S; Watts NB; Kendler D; Eriksen EF; Mesenbrink PG; Eastell R;
J Bone Miner Res; 2009 Sep; 24(9):1544-51. PubMed ID: 19338427
[TBL] [Abstract][Full Text] [Related]
16. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis.
Lindsay R; Scheele WH; Neer R; Pohl G; Adami S; Mautalen C; Reginster JY; Stepan JJ; Myers SL; Mitlak BH
Arch Intern Med; 2004 Oct; 164(18):2024-30. PubMed ID: 15477438
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters.
Arlot M; Meunier PJ; Boivin G; Haddock L; Tamayo J; Correa-Rotter R; Jasqui S; Donley DW; Dalsky GP; Martin JS; Eriksen EF
J Bone Miner Res; 2005 Jul; 20(7):1244-53. PubMed ID: 15940379
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
Boonen S; Marin F; Mellstrom D; Xie L; Desaiah D; Krege JH; Rosen CJ
J Am Geriatr Soc; 2006 May; 54(5):782-9. PubMed ID: 16696744
[TBL] [Abstract][Full Text] [Related]
19. Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk.
Reginster JY; Sarkar S; Zegels B; Henrotin Y; Bruyere O; Agnusdei D; Collette J
Bone; 2004 Feb; 34(2):344-51. PubMed ID: 14962813
[TBL] [Abstract][Full Text] [Related]
20. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass.
McClung MR; San Martin J; Miller PD; Civitelli R; Bandeira F; Omizo M; Donley DW; Dalsky GP; Eriksen EF
Arch Intern Med; 2005 Aug 8-22; 165(15):1762-8. PubMed ID: 16087825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
